Proactive Investors - Run By Investors For Investors

Archer Exploration prints human antibodies on graphene biosensors

The graphite from Archer’s Campoona Graphite Deposit in South Australia is structurally near perfect, even after mechanical and chemical processing.
An antibody ink formulation printed and patterned onto a resin-coated paper substrate
An antibody ink formulation printed and patterned onto a resin-coated paper substrate

Archer Exploration Ltd (ASX:AXE) has successfully printed and patterned ink formulations of human antibodies on graphene-based biosensor components derived from the company’s Campoona graphite.

Ink formulations comprised primarily of human antibody immunoglobulin G (IgG) as the active constituent were successfully prepared and printed using proprietary methods.

The IgG inks were printed on resin-coated paper and a number of graphene-based electrodes and were able to withstand the chemical and physical processes in the formulation, printing, and post-printing steps.

Background

Biological sensor devices are used in the detection and diagnosis of disease. The uniqueness of a biosensor is that its critical components are integrated into one sensor.

One of the biggest challenges to printable biosensors involves the scalable fabrication of integrated componentry capable of multiplexing – detecting a number of different diseases simultaneously using the same specimen.

The development of printable biosensors is envisioned to impact industries servicing human health, including point of care diagnostics and medical devices.

 

Archer CEO Dr Mohammad Choucair said: “We were able to formulate inks incorporating process compatible biomaterials provided by our German Biotech partners, and the team at the ARC Graphene Hub were able to print them on a number of our biosensor components.

“This concerted effort addressed a key technical barrier to realising a globally competitive biosensor, that of digitising the manufacturing of critical biosensor componentry that could allow for multiplexing.

“It has provided strong support for a number of claims in our provisional patent, which legally protects this competitive advantage and provides a means for commercial exploitation of the IP.”

Intellectual property and provisional patent publication

Archer’s provisional patent on the biosensor technology IP has been published in the Australian Official Journal of Patents.

The company is the sole applicant of the provisional patent, maintaining 100% ownership of the biosensor technology IP. Archer has until 15 February 2020 to consider maturing the application to a full patent.

View full AXE profile View Profile

Archer Exploration Limited Timeline

Related Articles

oil and gas operations
December 14 2018
The project is on schedule and on budget with tungsten production to start in February
Potash
March 05 2019
The company’s $5.3 million rights issue to fund completion of its DFS closes this week.
1551267092_Jupiter-Mines---Tshipi-ore.jpg
March 29 2019
The cash flow provides ballast against dilution, allowing the company carefully to consider each new opportunity on its merits

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use